Mortality in ankylosing spondylitis: results from a nationwide population-based study

Exarchou, Sofia; Lie, Elisabeth; Lindström, Ulf; Askling, Johan; Forsblad-d’Elia, Helena; Turesson, Carl; Kristensen, Lars Erik; Jacobsson, Lennart

doi:10.1136/annrheumdis-2015-207688

Cited by 93 publications

(94 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was the most current data available during model design. Newer data from a larger cohort suggested that SMR for AS were very close to our original assumptions, but the estimate of SMR for women was slightly higher than assumed in our study [37]. However, the results from DSA were not found to be remarkably sensitive to variation in mortality rates.…”

Section: Discussionsupporting

confidence: 62%

Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland

et al. 2018

View full text Add to dashboard Cite

Introduction: The aim of this study is to assess the cost-effectiveness of golimumab for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) vs. conventional therapy and other tumor necrosis factor inhibitors from the Scottish payer perspective. Methods: A model comprising a short-term decision tree and a long-term Markov model was developed to compare cost-effectiveness (incremental costs per quality-adjusted life-year [QALY]) for patients in Scotland with nr-axSpA treated by conventional therapy, adalimumab, certolizumab pegol, etanercept, or golimumab for a lifetime period. A network meta-analysis (NMA) was conducted to identify clinical and safety data for treatments and synthesize the available evidence into relative treatment effects between comparators. The probability of patients achieving an Assessment of SpondyloArthritis International Society 20/40% response criteria (ASAS20/ASAS40) or a 50% improvement in Bath Ankylosing Spondylitis

show abstract

Section: Discussionsupporting

confidence: 62%

Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland

et al. 2018

View full text Add to dashboard Cite

show abstract

“…В разных работах продемонстрировано увеличение стандартизованного показателя смертности у пациентов с АС с 1,6 до 1,9 [14][15][16]. Одна из основных причин леталь-ности при АС -ССЗ [17][18][19].…”

Section: общие принципыunclassified

According to the Materials of the 2015/2016 New European League Against Rheumatism (Eular) Guidelines for Reducing Cardiovascular Risk in Patients With Inflammatory Arthritis: General Characterization and Discussion Problems

Попкова¹,

Новикова²

2018

rsp

View full text Add to dashboard Cite

According to the materials of the 2015/2016 new European League Against Rheumatism (EULAR) guidelines for reducing cardiovascular risk in patients with inflammatory arthritis. The authors identify three main principles of prevention of cardiovascular diseases in rheumatoid arthritis and other chronic inflammatory arthritis and provide a general characterization of the guidelines, by reviewing the discussion problems.

show abstract

“…Инфекции оказывают значимое влияние на качество жизни пациентов с различными ревматическими забо-леваниями (РЗ) и являются одной из ведущих причин го-спитализации и летального исхода [1,2]. Так, у пациентов с ревматоидным артритом (РА) риск серьезных инфекций в 2 раза выше, чем в популяции, а риск смерти от инфек-ции выше, чем у лиц без РА соответствующего возраста [3,4].…”

Section: Introductionunclassified

Efficacy, safety and immunogenicity of a trivalent inactivated split influenza vaccine in patients with rheumatic diseases

Буханова¹,

Белов²,

Тарасова³

et al. 2018

Med. sov.

View full text Add to dashboard Cite

The aim of the study was to study the efficacy, safety and immunogenicity of trivalent split influenza vaccine in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic scleroderma (SSD). Material and methods. Ninety three patients were enrolled in the study, including 52 patients with RA, 34 with AS, 7 with SSD, and also 40 persons without rheumatic diseases (RD) (control group). At the time of enrolment, all patients received RD drug therapy. The duration of RD was from 2 months up to 46 years. Vaxigrip vaccine, which included the actual strains of influenza virus for the 2016-2017 or 2017-2018 seasons was administered subcutaneously in the amount of 1 dose (0.5 ml) against the backdrop of continuing RD therapy. The main stages of control were visits at 1-, 3- and 6-month intervals after vaccination. Standard clinical and laboratory tests, a clinical examination of the patient and assessment of disease activity were performed during the visits. Immunogenicity of the vaccine was evaluated at each stage of the control procedure using the commercial ELISA kits manufactured by PPDP LLC (St. Petersburg). Results. No cases of influenza or influenza-like illness were recorded during the entire period of observation. 81% of patients had no post-vaccination reactions in the RD group. Pain, swelling and hyperaemia of the skin with a diameter of up to 2 cm at the injection site were reported in 14% of cases and subfebrility, myalgia, malaise, headache in 5% of cases. The frequency of postvaccinal reactions among patients was not significantly different from that in the control group. There were no cases of exacerbation of RD or the occurrence of any new autoimmune disorders. The parameters of the humoral immune response in patients with RD did not significantly differ from those in the control group. Conclusion. The obtained data testify about good clinical efficacy and tolerability of trivalent split influenza vaccine in patients with RD.

show abstract

Mortality in ankylosing spondylitis: results from a nationwide population-based study

Abstract: Mortality was increased for male and female patients with AS. Predictors of death within the AS cohort included socioeconomic status, general comorbidities and hip replacement surgery.

Cited by 93 publications

References 26 publications

Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland

Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland

According to the Materials of the 2015/2016 New European League Against Rheumatism (Eular) Guidelines for Reducing Cardiovascular Risk in Patients With Inflammatory Arthritis: General Characterization and Discussion Problems

Efficacy, safety and immunogenicity of a trivalent inactivated split influenza vaccine in patients with rheumatic diseases

Contact Info

Product

Resources

About